Navigation Links
Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
Date:9/8/2008

WALTHAM, Mass., Sept. 8 /PRNewswire/ -- Logical Therapeutics, Inc., announced today the commencement of its double-blind, randomized, active-controlled, multinational study of LT-NS001, a novel prodrug, which is converted in the bloodstream to naproxen, a non-steroidal anti-inflammatory drug (NSAID). NSAIDs are the most common medications taken worldwide for the treatment of pain, inflammation, fever and arthritis, including both rheumatoid arthritis (RA) and osteoarthritis (OA).

"Despite a long history of successfully treating patients for pain and inflammation, NSAIDs have limitations that restrict their use. Gastrointestinal (GI) side effects are a significant safety problem," said Lutz Giebel, Chairman of Logical Therapeutics. Published studies have shown that NSAID use is responsible for 15-60% of hospital admissions for GI bleeding, amounting to approximately 100,000 hospitalizations and 10,000-20,000 deaths annually in the US. "A safer alternative would fulfill a significant unmet medical need," Dr. Giebel went on to say.

In pre-clinical studies in rats and dogs, LT-NS001 was shown to cause significantly less damage to the gastrointestinal tract than equivalent doses of naproxen. The study will assess gastrointestinal injury by endoscopy after 7 days of therapy. LT-NS001 was previously evaluated in two Phase 1 randomized, placebo-controlled, single-dose and multiple-dose pharmacokinetic studies. In all cases, LT-NS001 was well tolerated. Moreover, when the subjects were dosed twice daily with LT-NS001, plasma concentrations of naproxen were within the therapeutic range.

The Company also announced the departure of founding CEO, Dr. Mitchell P. Fink, who resigned to pursue other interests.

About Logical Therapeutics Inc.

Logical Therapeutics, Inc. is a privately held biotechnology company based in Waltham, Massachusetts. Logical Therapeutics is developing drugs to treat a variety of medical conditions that are associate
'/>"/>

SOURCE Logical Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
2. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
3. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
4. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
5. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
6. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
7. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
8. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
9. Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association
10. Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting
11. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...PRNewswire/ -- According to Millennium Research Gr...ogy market intelligence, the nearly $3 billion US ...o see rapid growth over the next five years despit...for Trauma Devices 2010 report finds that this ...ve years, with competitors introducing specialized...
(Date:11/25/2009)...nd JOHANNESBURG, November 25 ,iThem...covery announced today,that they have signed a col...ies, services. , Pyxis,s world class comp...ill be coupled with iThemba,s service division to ...to projects identified through Pyxis,internationa...
(Date:11/24/2009)...wire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX ...aortic disorders, announced today that it has file... in, the patent infringement lawsuit brought again...s filed in the United States District Court in Ind...that the stay remain in effect while the United St...
Breaking Medicine Technology:US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2First Catalog Cancer Biochip for Sequence Capture Now Available from febit 12991 1First Catalog Cancer Biochip for Sequence Capture Now Available from febit 12991 2Elsevier launches official version of BrainNavigator 51462 1Elsevier launches official version of BrainNavigator 51462 2Mystery E coli genes essential for survival of many species 9234 1Mystery E coli genes essential for survival of many species 9234 2
...INESS WIRE)--Mar 26, 2007 - Study results show,tha... (Lp-PLA2), a,cardiovascular-specific inflammatory...ead to heart attack and stroke, is,especially pred...metabolic syndrome--a serious medical condition th...s, which were presented yesterday,at the American ...
...ch 26, 2007 /PRNewswire/ -- Cleveland Clinic,resea...pite raising,high density lipoprotein cholesterol ...did not slow the progression of,plaque buildup in ...und probe. , Steven Nissen, M.D., Chairman of Card...nvestigator of this clinical trial, will,present t...
Other Medicine Technology:Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2,Predicts Heart Disease Risk in Metabolic Syndrome Patients 2Study Presented at the ACC Shows Inflammatory Enzyme Lp-PLA2,Predicts Heart Disease Risk in Metabolic Syndrome Patients 3Cholesterol Drug Fails to Slow Progression of Coronary Disease,Cleveland Clinic Study Reports 2Cholesterol Drug Fails to Slow Progression of Coronary Disease,Cleveland Clinic Study Reports 3Cholesterol Drug Fails to Slow Progression of Coronary Disease,Cleveland Clinic Study Reports 4
(Date:11/27/2009)... Biotech firm Replikins Ltd. today issued i...enomic data. It shows that the lethality of the v...uring the virus,s current outbreak in the spring o... 2.0 (s.d. 0.1). The H1N1 infectivity count, howev...Boston (PRWEB) November 27, 2009 -- Biotech firm R...
(Date:11/27/2009)...NCISCO, Nov. 27 The Gymb...lair Lambert, CFO/COO, will present at the NASDAQ ...he May Fair Hotel in London, England, on Wednesday...sten to a live broadcast of The Gymboree Corporati... to www.gymboree.com, click on "Our Company" at th...
(Date:11/27/2009)...LLY-SUR-SEINE, France, Nov. 27 Tea...al cycling team dedicated to ethical sporting and ...s, announced today that it will become Team Garmin...cal as a new sponsor of the team. Transitions Opti...e eyewear, offering the most advanced photochromic...
(Date:11/27/2009)... XenaCare Holdings has announced that it ha...ation, one of the largest nonprofit organizations ...education. , Delray Beach...s, Inc. (OTCBB: XCHO), a company specializing in t...ealthcare products, has announced today that is ha...
(Date:11/27/2009)...ring unprecedented medical, economic burdens, stud...y News) -- The number of people with diabetes in t...xt 25 years, a new study predicts. , That would...ple with the disease, up from 23.7 million today. ...e with diabetes will triple, the study also warns,...
Breaking Medicine News(10 mins):Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3
...Efficacy Studies Will Be Highlighted, TAMPA, Fla.... in the United States. More than 25 million,Americ... a result of,injuries or surgeries, and a recent s...tadol immediate release (IR),tablets for acute pai...
...iven injections of ghrelin showed activity in brai...ealthDay News) -- A new brain imaging study reveal...ing powers actually stimulates key reward centers ...hedonic effect" on the senses unfolds in the same ...
... ROCHESTER, N.Y., May 7 Digital medical imaging a...Inc., is playing a key role in helping The Field M...en within its world-class collections. , Carestrea...ges from more than one million priceless specimens...
...(Monday, May 5, 2008) Health care in the United S...ause it also is a major contributor to the economy...ring in the June 2008 issue of the Journal of the ...ich funds medical research that leads to potential...
... The gender gap is alive and well in heart diseas...fering from men on everything from symptoms to tre... , One of the most striking findings was that wo...0 percent of any one blood vessel. , This was de...
...Hospitals in Louisiana and,Mississippi still worki...will receive $19.1 million in additional assistanc... (HHS)., "HHS continues to work with those in nee...re the citizens of these,states have continued acc...
Other Medicine News:Health News:Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annual Meeting 2Health News:Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annual Meeting 3Health News:Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annual Meeting 4Health News:Hunger Hormone Makes Food Look More Tasty 2Health News:Hunger Hormone Makes Food Look More Tasty 3Health News:X-rays power discoveries at Chicago's Field Museum 2Health News:X-rays power discoveries at Chicago's Field Museum 3Health News:Medical research is essential to improving the economy and bettering lives 2Health News:Women and heart attack: Study finds failure to recognize symptoms, failure to treat appropriately 2Health News:Women and heart attack: Study finds failure to recognize symptoms, failure to treat appropriately 3Health News:Hospitals in Louisiana and Mississippi to Receive More Katrina Recovery Grants 2
...iratory Products, ,Westmed designs, manufacturers...nesthesia and Respiratory professionals. Our missi...nce the clinician's ability to deliver quality med...om line. , ,Our web site is designed with our cus...
...iratory Products, ,Westmed designs, manufacturers...nesthesia and Respiratory professionals. Our missi...nce the clinician's ability to deliver quality med...om line. , ,Our web site is designed with our cus...
...lizer achieves optimum lung penetration for maximu...ze range is 1.04-1.10 µ at 6-8 LPM. Latex-fr...t., ,As the world leader in airway management pro...rance of proven technology by offering top brands ...
...lizer achieves optimum lung penetration for maximu...ze range is 1.04-1.10 µ at 6-8 LPM. Latex-fr...t., ,As the world leader in airway management pro...rance of proven technology by offering top brands ...
Medicine Products: